38 results on '"Wartel, T. Anh"'
Search Results
2. Efficacy of a bivalent (D614 + B.1.351) SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant in adults: a phase 3, parallel, randomised, modified double-blind, placebo-controlled trial
3. Efficacy of a monovalent (D614) SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant in adults: a phase 3, multi-country study
4. COVID-19 Vaccines Authorized by Stringent Regulatory Authorities and Vaccine Candidates Expecting Approval in 2021
5. Immune non-interference and safety study of Vi-DT typhoid conjugate vaccine with a measles, mumps and rubella containing vaccine in 9–15 months old Nepalese infants
6. A Phase 3, Multicenter, Randomized, Controlled Trial to Evaluate Immune Equivalence and Safety of Multidose and Single-dose Formulations of Vi-DT Typhoid Conjugate Vaccine in Healthy Filipino Individuals 6 Months to 45 Years of Age
7. Immune persistence and response to booster dose of Vi-DT vaccine at 27.5 months post-first dose
8. Safety and immunogenicity of the Vi-DT typhoid conjugate vaccine in healthy volunteers in Nepal: an observer-blind, active-controlled, randomised, non-inferiority, phase 3 trial
9. Safety and immunogenicity of Vi-DT conjugate vaccine among 6-23-month-old children: Phase II, randomized, dose-scheduling, observer-blind Study
10. Efficacy of a bivalent (D614 + B.1.351) SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant in adults: a phase 3, parallel, randomised, modified double-blind, placebo-controlled trial
11. Efficacy of a monovalent (D614) SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant in adults: a phase 3, multi-country study
12. Replication and Excretion of the Live Attenuated Tetravalent Dengue Vaccine CYD-TDV in a Flavivirus-Naive Adult Population : Assessment of Vaccine Viremia and Virus Shedding
13. Three Decades of Dengue Surveillance in Five Highly Endemic South East Asian Countries : A Descriptive Review
14. Detection of dengue cases by serological testing in a dengue vaccine efficacy trial: Utility for efficacy evaluation and impact of future vaccine introduction
15. Hepatitis E vaccine—Illuminating the barriers to use
16. Single Ad26.COV2.S Booster Dose Following Two Doses of BBIBP-CorV Vaccine Against SARS-CoV-2 Infection in Adults: Day 28 Results of a Phase 1/2 Open-Label Trial
17. Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial
18. Factors affecting willingness to participate in vaccine clinical trials in an underdeveloped country: perspective from Nepal
19. A randomized, observer-blind, controlled phase III clinical trial assessing safety and immunological non-inferiority of Vi-diphtheria toxoid versus Vi-tetanus toxoid typhoid conjugate vaccine in healthy volunteers in eastern Nepal.
20. Acute respiratory distress syndrome (ARDS) as an adverse event following immunization: Case definition & guidelines for data collection, analysis, and presentation of immunization safety data
21. Challenges and opportunities in setting up a phase III vaccine clinical trial in resource limited settings: Experience from Nepal
22. Vaccination against SARS-CoV-2 and disease enhancement – knowns and unknowns
23. Review on the Recent Advances on Typhoid Vaccine Development and Challenges Ahead
24. Immunogenicity, safety and reactogenicity of a Phase II trial of Vi-DT typhoid conjugate vaccine in healthy Filipino infants and toddlers: A preliminary report
25. Long-term immunogenicity and safety of tetravalent dengue vaccine (CYD-TDV) in healthy populations in Singapore and Vietnam: 4-year follow-up of randomized, controlled, phase II trials
26. Immunogenicity and safety of a tetravalent dengue vaccine during a five-year follow-up period
27. Symptomatic Dengue Disease in Five Southeast Asian Countries: Epidemiological Evidence from a Dengue Vaccine Trial
28. Safety Overview of a Recombinant Live-Attenuated Tetravalent Dengue Vaccine: Pooled Analysis of Data from 18 Clinical Trials
29. Symptomatic Dengue in Children in 10 Asian and Latin American Countries
30. Efficacy and Long-Term Safety of a Dengue Vaccine in Regions of Endemic Disease
31. Immunogenicity and safety of a tetravalent dengue vaccine in healthy adults in India: A randomized, observer-blind, placebo-controlled phase II trial
32. Challenges in the clinical development of a dengue vaccine
33. Immunogenicity and safety of a tetravalent dengue vaccine in healthy adults in India: A randomized, observer-blind, placebo-controlled phase II trial.
34. Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial
35. Immunogenicity and safety of recombinant tetravalent dengue vaccine (CYD-TDV) in individuals aged 2–45 years
36. Immunogenicity and safety of recombinant tetravalent dengue vaccine (CYD-TDV) in individuals aged 2-45 y.
37. Symptomatic Dengue in Children in 10 Asian and Latin American Countries.
38. Efficacy of a bivalent (D614 + B.1.351) SARS-CoV-2 Protein Vaccine.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.